此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants

2026年9月20日 更新者:Shanghai Argo Biopharmaceutical Co., Ltd.

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of A Single Dose of BW-50218 in Healthy Chinese Participants

A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants

研究概览

详细说明

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of A Single Dose of BW-50218 in Healthy Chinese Participants

研究类型

介入性

注册 (实际的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Shanghai、中国
        • Argo Investigative Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Capable of providing written informed consent and complying with all study procedures for the duration of the study.
  • Body weight > 50 kg for males and > 45 kg for females; body mass index (BMI) within a range considered appropriate for study participation by the investigator.
  • Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.
  • Male participants with partners of childbearing potential must agree to use effective contraception.

Exclusion Criteria:

  • Any clinically significant chronic medical condition or clinically significant abnormality in physical examination that, in the opinion of the Investigator, makes the participant unsuitable for participation in the study.
  • Recent hospitalization or a significant acute medical event.
  • History of cancer or any long-term medical condition that the study doctor considers clinically relevant.
  • Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.
  • Positive test for hepatitis B, hepatitis C, or HIV.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:BW-50218 Dose1

Single dose of BW-50218 injection (Dose 1)

Solution for injection

实验性的:BW-50218 Dose 2

Single dose of BW-50218 injection (Dose 2)

Solution for injection

实验性的:BW-50218 Dose 3

Single dose of BW-50218 injection (Dose 3)

Solution for injection

安慰剂比较:Saline Placebo

Single dose of Saline Placebo

Solution for injection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAES)
大体时间:From baseline up to Day 360 (End of Study)

Evaluation of the number of participants with treatment-emergent adverse events and serious adverse events. The severity of AEs will be assessed and categorized according to the "Guidance for industry: Toxicity Grading Scale for Healthy Adultand Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" (FDA, 2007).

From baseline up to Day 360 (End of Study)
Hematology results (Platelets, 10^9/L) at each time point, including changes from baseline to Day 360 post dose will be summarized by treatment group.
大体时间:From baseline up to Day 360 (End of Study)

The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged.

From baseline up to Day 360 (End of Study)
Hematology results (concentration of Hemoglobin, g/L) at each time point, including changes from baseline to Day 360 post dose will be summarized by treatment group.
大体时间:From baseline up to Day 360 (End of Study)

The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged.

From baseline up to Day 360 (End of Study)
Chemistry results (Albumin, g/L) at each time point from baseline to Day 360 will be summarized bytreatment group.
大体时间:From baseline up to Day 360 (End of Study)

The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged.

From baseline up to Day 360 (End of Study)
Chemistry results (Alkaline Phosphatase, U/L; Alanine Aminotransferase, U/L; Aspartate Aminotransferase, U/L) at each time point from baseline to Day 360 will be summarized bytreatment group.
大体时间:From baseline up to Day 360 (End of Study)

The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged.

From baseline up to Day 360 (End of Study)
Chemistry results (Direct Bilirubin, umol/L) at each time point from baseline to Day 360 will be summarized bytreatment group.
大体时间:From baseline up to Day 360 (End of Study)

The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged.

From baseline up to Day 360 (End of Study)
Urinalysis results (Epithelial cells, crystals, casts, bilirubin) at each time point,including change from baseline to Day 360 post dose will be summarized in thetable by treatment group.
大体时间:From baseline up to Day 360 (End of Study)

The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be fagged.

From baseline up to Day 360 (End of Study)
Vital signs (Blood pressures, millimeters of mercury) changes from Baselinevalues to Day 360 post dose will be summarized in the table by treatment group
大体时间:From baseline up to Day 360 (End of Study)

Abnormal physical examination findings will be listed.

From baseline up to Day 360 (End of Study)
Vital signs (Heart rate, beats per minute) changes from Baseline values to Day 360 post dose will be summarized in the table by treatment group.
大体时间:From baseline up to Day 360 (End of Study)

Abnormal physical examination findings will be listed.

From baseline up to Day 360 (End of Study)
Vital signs (Respiratory rate, times per minute) changes from Baseline values to Day 360 post dose will be summarized in the table by treatment group.
大体时间:From baseline up to Day 360 (End of Study)

Abnormal physical examination findings will be listed.

From baseline up to Day 360 (End of Study)
Vital signs (Temperature,degrees Celsius) changes from Baseline values to Day 360 post dose will be summarized in the table by treatment group.
大体时间:From baseline up to Day 360 (End of Study)

Abnormal physical examination findings will be listed.

From baseline up to Day 360 (End of Study)
Changes in ECG (PR Interval, msec; QRs Duration, msec;QT interval, msec; RR interval, msec; QTcF Interval, msec; ) from Baseline to Day 360 post-dose will be summarized.
大体时间:From baseline up to Day 360 (End of Study)

12-lead ECGs will be summarized by visit and by treatment group, along with the changes from baseline.The summary of overall interpretation findings table presented counts and percentages for the reported results at Baseline and Day 360/time point. Result categories were ordered as "Normal", "Abnormal Not Clinically Significant (NCS)" and "Abnormal Clinically Significant (CS)"(categorical descriptive analysis).

From baseline up to Day 360 (End of Study)
Changes in ECG (Mean heart rate, bpm ) from Baseline to Day 360 post-dose will be summarized.
大体时间:From baseline up to Day 360 (End of Study)

12-lead ECGs will be summarized by visit and by treatment group, along with the changes from baseline.The summary of overall interpretation findings table presented counts and percentages for the reported results at Baseline and Day 360/time point. Result categories were ordered as "Normal", "Abnormal Not Clinically Significant (NCS)" and "Abnormal Clinically Significant (CS)"(categorical descriptive analysis).

From baseline up to Day 360 (End of Study)
Change from Baseline in Physical Examination Findings
大体时间:From baseline up to Day 360 (End of Study)

Assessment of clinically significant changes in physical examination findings

From baseline up to Day 360 (End of Study)
Hematology results (Red blood cell count, 10^12/L) at each time point, including changes from baseline to Day 360 post dose will be summarized by treatment group.
大体时间:From baseline up to Day 360 (End of Study)

The safety laboratory data will be summarized by visit and by treatment group, along with changes from baseline. The values that are below the lower limit or above the upper limit ofthe reference range will be flagged for safety. Those values or changes in values that are identified as being clinically significant will be flagged.

From baseline up to Day 360 (End of Study)

次要结果测量

结果测量
措施说明
大体时间
Maximum Observed Plasma Concentration (Cmax)
大体时间:From pre-dose up to Day 8

Evaluation of the maximum plasma concentration of BW-50218.

From pre-dose up to Day 8
Time to Maximum Plasma Concentration (Tmax)
大体时间:From pre-dose up to Day 8

Evaluation of the time to reach maximum plasma concentration.

From pre-dose up to Day 8
Area Under the Plasma Concentration-Time Curve (AUC)
大体时间:From pre-dose up to Day 8

Evaluation of AUc from time zero to 24 hours (AUC0-24), to 48 hours (AUC0-48), and to infinity (AUC0-inf)

From pre-dose up to Day 8
Terminal Elimination Half-Life (t1/2)
大体时间:From pre-dose up to Day 8

Evaluation of the elimination half-life of BW-50218

From pre-dose up to Day 8
Urine Pharmacokinetic Parameters (Renal Clearance, CLr)
大体时间:From pre-dose up to 24 hours post-dose

Renal clearance calculated as CLr = CAe/Plasma AUC 0-24. Ae=cumulative amount excreted in urine (mg). AUC 0-24 = Area under the plasma concentration - time curve from 0 to 24 hours(e.g.mg*h/mL)

From pre-dose up to 24 hours post-dose

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Yuqiong Li、Shanghai Argo Biopharmaceutical Co., Ltd.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月18日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2028年4月30日

研究注册日期

首次提交

2026年4月13日

首先提交符合 QC 标准的

2026年5月5日

首次发布 (实际的)

2026年5月11日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月20日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • BW-50218-1002

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

A decision regarding sharing of de-identified IPD will be made by the Sponsor after study completion and will consider scientific merit, participant privacy, and regulatory requirements.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅